Table 2.
Medical and demographic characteristics of the participants
| Variables | Intervention group (n=41), n(%) | Control group (n=43), n(%) |
|---|---|---|
| Sex | ||
| Female | 22 (53.7) | 26 (60.5) |
| Male | 19 (46.3) | 17 (39.5) |
| Age, median (IQR) | 72.1 (67.3-74.5) | 71.5 (68.5-75.3) |
| Diagnosis | ||
| Pancreatic cancer | 17 (41.5) | 19 (44.2) |
| Biliary tract cancer | 5 (12.2) | 4 (9.3) |
| Non-small cell lung cancer | 19 (46.3) | 20 (46.5) |
| Cancer stage | ||
| Locally advanced | 6 (14.6) | 6 (14.0) |
| Metastatic | 35 (85.4) | 37 (86.1) |
| Time since cancer diagnosis, in days, median (IQR) | 43 (29-53) | 35 (27-54) |
| Current treatment (first-line) | ||
| Chemotherapy | 30 (73.2) | 31 (72.1) |
| Immunotherapy | 6 (14.6) | 8 (18.6) |
| Chemotherapy/immunotherapy (combination) | 2 (4.9) | 2 (7.0) |
| Targeted therapy | 3 (7.3) | 2 (7.0) |
| Charlson comorbidity score | ||
| 0 | 14 (34.1) | 12 (27.9) |
| 1 | 10 (24.4) | 10 (23.3) |
| 2 | 11 (26.8) | 13 (30.2) |
| 3 | 4 (9.8) | 6 (14.0) |
| ≥4 | 2 (4.8) | 2 (4.6) |
| Performance status | ||
| 0 | 18 (43.9) | 27 (62.8) |
| 1 | 19 (46.3) | 15 (34.9) |
| 2 | 4 (9.8) | 1 (2.3) |
| Body Mass Index, median (IQR) | 23.0 (21.3-25.5) | 23.9 (20.8-26.8) |
| Living situation | ||
| Co-living | 25 (61.0) | 32 (74.4) |
| Living alone | 16 (39.0) | 11 (25.6) |
| Employment status | ||
| Retired | 35 (85.4) | 38 (88.4) |
| Working (full or part time) | 6 (14.6) | 5 (11.6) |
| Saltin-Grimby Physical Activity Level Scale | ||
| Level 1 (sedentary) | 12 (29.3) | 4 (9.3) |
| Level 2 (light) | 13 (31.7) | 17 (39.5) |
| Level 3 (moderate) | 11 (26.8) | 15 (34.9) |
| Level 4 (active) | 5 (12.2) | 7 (16.3) |
Abbreviation: IQR, interquartile range.